Schroder Investment Management Group
ONCE

Schroder Investment Management Group’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Schroder Investment Management Group’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-9,801
Closed -$489K – 1285
2016
Q4 		$489K Buy
+9,801
New +$525K ﹤0.01% 973

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return

Schroder Investment Management Group's ONCE Position: Q1 2017 in Review

Schroder Investment Management Group sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2017, closing a stake of 9,801 shares — an estimated $489K sold.

Schroder Investment Management Group first reported a position in ONCE in Q4 2016 and held it in 1 quarter. The position peaked at $489K in Q4 2016. 122 funds tracked by Wall St. Rank hold ONCE as of Q1 2017.

  • Schroder Investment Management Group reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Schroder Investment Management Group sold 9,801 Spark Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $489K.
  • Schroder Investment Management Group first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2016 and held it in 1 quarter.
  • Schroder Investment Management Group's Spark Therapeutics, Inc. Common Stock position peaked at $489K in Q4 2016.
  • 122 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Schroder Investment Management Group's 13F filing for Q1 2017, filed 10 May 2017.